ADMP
Adamis Pharmaceuticals Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
adamis pharmaceuticals corporation (nasdaq: admp) is a specialty biopharmaceuticals company focused on developing and commercializing products in the therapeutic areas of respiratory disease, allergies, oncology and immunology. its specialty pharmaceutical division currently has four products in its pipeline including the epinephrine injection pre-filled syringe (pfs) for use in the emergency treatment of anaphylaxis, apc-1000 and apc-5000 (dry powder inhaler) for the treatment of asthma and chronic obstructive pulmonary disease (copd), and apc-3000, a hydrofluoroalkane (hfa) inhaled nasal steroid product for the treatment of allergic rhinitis. this division’s focus is to create low cost therapeutic alternatives to existing treatments in large markets. adamis will pursue 505(b)(2) regulatory approval filings in order to minimize costs and shorten the time to market in this division. within its biotechnology division, the company has four products under development include telob-vax, a
Market Cap: 7.19 Million
Primary Exchange: NASDAQ
Website: http://www.adamispharmaceuticals.com/
Shares Outstanding: 9.36 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.0
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2863 trading days
From: 2013-02-12 To: 2023-05-19
Lowest Point:
Adamis: Share Price Continues To Grind Down To A Fine Discount
via: SeekingAlpha at 2019-06-13 04:24:20:000
Adamis Pharmaceuticals ( ADMP ) is a specialty biopharmaceutical company dedicated to developing and commercializing various therapeutic products. The company's leading product, SYMJEPI, is a pre-filled syringe "PFS" device holding 0.3mg or 0.15mg dosage of epinephrine that has FDA approval fo… read more...
Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval
via: SeekingAlpha at 2019-06-11 07:39:43:000
Based on FDA feedback, Adamis Pharmaceuticals ( ADMP -4.5% ) has removed kalo's EVZIO (naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug (RLD) in its marketing application seeking approval for its higher dose naloxone injection product for the emergency trea… read more...
Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval
via: SeekingAlpha at 2019-06-11 07:39:43:000
Based on FDA feedback, Adamis Pharmaceuticals ( ADMP -4.5% ) has removed kalo's EVZIO (naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug (RLD) in its marketing application seeking approval for its higher dose naloxone injection product for the emergency trea… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2013-12-13 | 17.0 | 1.0 | 17.0 |